Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2019 | 06-2019 | 03-2019 | 12-2018 | 09-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 593,576 | 536,058 | 268,631 | 2,087,103 | 562,007 |
| Depreciation Amortization | 80,685 | 54,838 | 27,140 | 72,420 | 53,594 |
| Income taxes - deferred | 94,175 | 87,358 | 43,425 | -1,512,325 | 3,595 |
| Accounts receivable | -41,444 | -55,870 | -30,136 | -108,152 | -75,167 |
| Accounts payable and accrued liabilities | -12,210 | -28,074 | -24,145 | 36,554 | 23,023 |
| Other Working Capital | 155,915 | 20,873 | -62,221 | 238,020 | 154,835 |
| Other Operating Activity | 252,625 | 173,350 | 102,090 | 456,666 | 233,821 |
| Operating Cash Flow | $1,123,322 | $788,533 | $324,784 | $1,270,286 | $955,708 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -58,690 | -34,399 | -18,041 | -95,449 | -79,803 |
| Net Acquisitions | -245,824 | N/A | N/A | N/A | N/A |
| Purchase Of Investment | -408,958 | -283,636 | -128,215 | -515,389 | -389,857 |
| Sale Of Investment | 375,145 | 228,707 | 107,118 | 431,576 | 308,406 |
| Other Investing Activity | 0 | 0 | 0 | -22,896 | 0 |
| Investing Cash Flow | $-338,327 | $-89,328 | $-39,138 | $-202,158 | $-161,254 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 1,002 | 1,002 | N/A | 20,840 | 12,983 |
| Debt Repayment | -33,195 | -18,926 | N/A | -33,388 | -28,372 |
| Common Stock Issued | 144,630 | 114,092 | 63,620 | 289,293 | 245,754 |
| Common Stock Repurchased | -150,017 | -150,017 | -94,007 | -350,043 | -207,038 |
| Other Financing Activity | 2,932 | -1,155 | -11,602 | 2,079 | 6,500 |
| Financing Cash Flow | $-34,648 | $-55,004 | $-41,989 | $-71,219 | $29,827 |
| Exchange Rate Effect | -4,009 | -808 | -378 | -6,182 | -4,756 |
| Beginning Cash Position | 2,658,253 | 2,658,253 | 2,658,253 | 1,667,526 | 1,667,526 |
| End Cash Position | 3,404,591 | 3,301,646 | 2,901,532 | 2,658,253 | 2,487,051 |
| Net Cash Flow | $746,338 | $643,393 | $243,279 | $990,727 | $819,525 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,123,322 | 788,533 | 324,784 | 1,270,286 | 955,708 |
| Capital Expenditure | -58,690 | -34,399 | -18,041 | -95,449 | -79,803 |
| Free Cash Flow | 1,064,632 | 754,134 | 306,743 | 1,174,837 | 875,905 |